lb-100 and Non-alcoholic-Fatty-Liver-Disease

It is well known that nonalcoholic fatty liver disease (NAFLD) is associated with insulin resistance (IR). LB100, a serine/threonine protein phosphatase 2A (PP2A) inhibitor, is closely related to IR. However, there is little data regarding its direct influence on NAFLD.. To elucidate the effect and underlying mechanism of LB100 in NAFLD.. After 10 wk of high fat diet (HFD) feeding, male C57BL/6 mice were injected intraperitoneally with vehicle or LB100 for an additional 6 wk (three times a week). The L02 cell line was treated with LB100 and free fatty acids (FFAs) for 24 h. Hematoxylin and eosin and oil red O staining were performed for histological examination. Western blot analysis was used to detect the protein expression of Sirtuin 1 (Sirt1), total and phosphorylated AMP-activated protein kinase α (AMPKα), and the proteins involved in lipogenesis and fatty acid oxidation. The mRNA levels were determined by qPCR. Pharmacological inhibition of AMPK was performed to further examine the exact mechanism of LB100 in NAFLD.

Topics: Acyl-CoA Oxidase; AMP-Activated Protein Kinases; Animals; Carnitine O-Palmitoyltransferase; Diet, High-Fat; Disease Models, Animal; Enzyme Inhibitors; Fatty Acids; Gene Expression Regulation; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oxygen; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Piperazines; PPAR alpha; Protein Phosphatase 2; Signal Transduction; Sirtuin 1; Uncoupling Protein 2